The Latest
Gene Therapy Shows Promise for Early Intervention in Cardiovascular Disease And Stroke
A new gene-editing therapy called VERVE-101 has shown promising results in lowering LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia (HeFH), a genetic disorder that causes dangerously high levels of “bad” cholesterol.
























